Pfizer gets fresh cancer drug rejection from UK cost body

LONDON, July 16 Mon Jul 15, 2013 7:01pm EDT

LONDON, July 16 (Reuters) - Pfizer's new chronic myeloid leukaemia drug Bosulif - also known as bosutinib - is too expensive to be used by Britain's state health service, the country's cost agency NICE said on Tuesday.

The latest draft guidance from the National Institute for Health and Clinical Excellence (NICE), which is subject consultation, follows two earlier rebuffs for new cancer drugs developed by Pfizer this year.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.